|
审核状态: Project audit state: |
通过审核 Successful |
|
注册号: Registration number: |
ChiCTR2600122397 |
|
最近更新日期: Date of Last Refreshed on: |
2026-04-13 16:24:05 |
|
注册时间: Date of Registration: |
2026-04-13 00:00:00 |
|
注册号状态: |
预注册 |
|
Registration Status: |
Prospective registration |
|
注册题目: |
体外心肺复苏辅助急性心肌梗死伴心跳骤停患者治疗的预后及影响因素 |
|
Public title: |
Prognosis and influencing factors of ECPR in the treatment of patients with AMI-CA |
|
注册题目简写: |
|
|
English Acronym: |
|
|
研究课题的正式科学名称: |
体外心肺复苏辅助急性心肌梗死伴心跳骤停患者治疗的预后及影响因素 |
|
Scientific title: |
Prognosis and influencing factors of extracorporeal cardiopulmonary resuscitation in the treatment of patients with acute myocardial infarction complicated by cardiac arrest |
|
研究课题代号(代码): Study subject ID: |
|
|
在二级注册机构或其它机构的注册号: The registration number of the Partner Registry or other register: |
|
申请注册联系人: |
范晓岚 |
研究负责人: |
李斌飞 |
|
Applicant: |
Fan Xiao Lan |
Study leader: |
Libinfei |
|
申请注册联系人电话: Applicant telephone: |
+86 189 3337 1826 |
研究负责人电话:
Study leader's |
+86 760 8988 0319 |
|
申请注册联系人传真 : Applicant Fax: |
研究负责人传真: Study leader's fax: |
||
|
申请注册联系人电子邮件: Applicant E-mail: |
1242305039@qq.com |
研究负责人电子邮件: Study leader's E-mail: |
libinfei@163.com |
|
申请单位网址(自愿提供): Applicant website(voluntary supply): |
研究负责人网址(自愿提供): Study leader's website(voluntary supply): |
||
|
申请注册联系人通讯地址: |
广东省中山市孙文东路2号中山市人民医院 |
研究负责人通讯地址: |
中山市石岐区孙文东路2号 |
|
Applicant address: |
Zhongshan People's Hospital 2 East Sunwen Road, Zhongshan, Guangdong, P.R.China |
Study leader's address: |
No.2 Sunwen East Road,Zhongshan City, Guangdong, China |
|
申请注册联系人邮政编码: Applicant postcode: |
研究负责人邮政编码: Study leader's postcode: |
||
|
申请人所在单位: |
中山市人民医院 |
||
|
Applicant's institution: |
Zhongshan People's Hospital |
||
|
研究负责人所在单位: |
中山市人民医院 |
||
|
Affiliation of the Leader: |
Zhongshan People’s Hospital(Affiliated Zhongshan Hospital of Sun Yat-sen University) |
||
|
是否获伦理委员会批准: |
是 |
||
|
Approved by ethic committee: |
Yes |
||
|
伦理委员会批件文号: Approved No. of ethic committee: |
K2026-014 |
伦理委员会批件附件: Approved file of Ethical Committee: |
查看附件View |
|
批准本研究的伦理委员会名称: |
中山市人民医院临床科研与实验动物伦理委员会 |
||
|
Name of the ethic committee: |
Ethics Committee of Clinical Research and Experimental Animals of Zhongshan Peoples Hospital |
||
|
伦理委员会批准日期: Date of approved by ethic committee: |
2026-03-24 00:00:00 | ||
|
伦理委员会联系人: |
林贤珊 |
||
|
Contact Name of the ethic committee: |
Lin XianShan |
||
|
伦理委员会联系地址: |
中山市石岐区孙文东路2号 |
||
|
Contact Address of the ethic committee: |
No.2 Sunwen East Road,Zhongshan City, Guangdong, China |
||
|
伦理委员会联系人电话: Contact phone of the ethic committee: |
+86 760 8988 0030 |
伦理委员会联系人邮箱: Contact email of the ethic committee: |
249210847@qq.com |
|
研究实施负责(组长)单位: |
中山市人民医院 |
||||||||||||||||||||||
|
Primary sponsor: |
Zhongshan People’s Hospital(Affiliated Zhongshan Hospital of Sun Yat-sen University) |
||||||||||||||||||||||
|
研究实施负责(组长)单位地址: |
中山市石岐区孙文东路2号 |
||||||||||||||||||||||
|
Primary sponsor's address: |
No.2 Sunwen East Road,Zhongshan City, Guangdong, China |
||||||||||||||||||||||
|
试验主办单位(项目批准或申办者): Secondary sponsor: |
|
||||||||||||||||||||||
|
经费或物资来源: |
自选课题(自筹) |
||||||||||||||||||||||
|
Source(s) of funding: |
Self-financed |
||||||||||||||||||||||
|
研究疾病: |
急性心肌梗死合并心脏骤停 |
||||||||||||||||||||||
|
Target disease: |
Acute myocardial infarction complicated by cardiac arrest |
||||||||||||||||||||||
|
研究疾病代码: |
|
||||||||||||||||||||||
|
Target disease code: |
|
||||||||||||||||||||||
|
研究类型: |
观察性研究 |
||||||||||||||||||||||
|
Study type: |
Observational study |
||||||||||||||||||||||
|
研究所处阶段: |
其它 | ||||||||||||||||||||||
|
Study phase: |
N/A |
||||||||||||||||||||||
|
研究设计: |
队列研究 |
||||||||||||||||||||||
|
Study design: |
Cohort study |
||||||||||||||||||||||
|
研究目的: |
本研究旨在系统分析ECPR辅助治疗AMI-CA患者的临床预后特征,并筛选影响患者院内死亡的独立危险因素,量化各临床指标对患者预后的预测效能,构建可靠的预后预测模型,从而为评估该类患者死亡风险评估提供新思路。 |
||||||||||||||||||||||
|
Objectives of Study: |
This study aims to systematically analyze the clinical prognostic characteristics of AMI-CA patients treated with ECPR, screen out independent risk factors affecting in-hospital mortality of patients, quantify the predictive efficacy of various clinical indicators on patient prognosis, and construct a reliable prognostic prediction model, thereby providing new ideas for assessing the risk of death in such patients. |
||||||||||||||||||||||
|
药物成份或治疗方案详述: |
|
||||||||||||||||||||||
|
Description for medicine or protocol of treatment in detail: |
|
||||||||||||||||||||||
|
纳入标准: |
1. 年龄>=18周岁,性别不限; 2. 因AMI-CA在住院期间首次接受VA-ECMO支持治疗的患者; 3. 治疗期间相关临床诊疗记录、实验室检测数据及院内随访资料完整,数据可追溯、可提取,能够满足本研究数据整理及统计分析的相关要求; 4. CA发生后,已及时接受CCPR干预,并在此基础上启动ECPR辅助治疗。 |
||||||||||||||||||||||
|
Inclusion criteria |
1. Aged >= 18 years, regardless of gender; 2. Patients who received VA-ECMO support therapy for the first time during hospitalization due to AMI-CA; 3. Relevant clinical diagnosis and treatment records, laboratory test data, and in-hospital follow-up data during treatment are complete, and the data are traceable and extractable, which can meet the relevant requirements of data collation and statistical analysis in this study; 4. After the occurrence of CA, timely CCPR intervention was received, and on this basis, ECPR adjuvant therapy was initiated. |
||||||||||||||||||||||
|
排除标准: |
1. 非AMI引发的CA患者; 2. VA-ECMO辅助后24h内死亡,且无完整临床资料的患者; 3. 存在严重不可逆性疾病(如恶性肿瘤晚期、终末期肾病/肝病、严重脑器质性疾病); 4. 妊娠期或哺乳期女性; 5. 家属拒绝ECPR治疗或中途放弃治疗,且无完整随访资料的患者; 6. 临床病历资料不全,无法提取研究所需核心数据的患者。 |
||||||||||||||||||||||
|
Exclusion criteria: |
1. Patients with CA not caused by AMI; 2. Patients who died within 24 hours after VA-ECMO support and had incomplete clinical data; 3. Patients with severe irreversible diseases (such as advanced malignant tumors, end-stage renal disease/liver disease, severe cerebral organic diseases); 4. Pregnant or lactating women; 5. Patients whose family members refused ECPR treatment or gave up treatment midway and had incomplete follow-up data; 6. Patients with incomplete clinical medical records, making it impossible to extract core data required for the study. |
||||||||||||||||||||||
|
研究实施时间: Study execute time: |
从 From 2026-04-01 00:00:00至 To 2026-06-30 00:00:00 |
征募观察对象时间: Recruiting time: |
从 From 2026-04-13 00:00:00 至 To 2026-06-30 00:00:00 |
|
干预措施: Interventions: |
|
|
研究实施地点: Countries of recruitment and research settings: |
|
||||||||||||||||||||||||||||
|
测量指标: Outcomes: |
|
|
采集人体标本:
Collecting sample(s)
|
|
|
征募研究对象情况: Recruiting status: |
尚未开始 Not yet recruiting |
年龄范围: Participant age: |
|
||||||
|
性别: |
男女均可 |
Gender: |
Both |
||||||
|
随机方法(请说明由何人用什么方法产生随机序列): |
无 |
||||||||
|
Randomization Procedure (please state who generates the random number sequence and by what method): |
None |
||||||||
|
是否公开试验完成后的统计结果: Calculated Results after the Study Completed public access: |
不公开/Private |
|
盲法: |
无 |
|
Blinding: |
None |
|
是否共享原始数据: IPD sharing |
否No |
|
共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址): |
受伦理及患者隐私保护限制,不公开共享原始数据 |
|
The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url): |
Due to ethical restrictions and patient privacy protection, the original data cannot be publicly shared |
|
数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC: |
本研究依据精心设计的病例报告表(CRF)进行数据收集,所有数据均通过电子数据采集系统(EDC)进行实时录入与管理,确保数据的完整性与准确性 |
|
Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture: |
Data were collected based on a well-designed Case Report Form (CRF) and real-time entered and managed through an electronic data capture system (EDC) to ensure data integrity and accuracy. |
|
数据与安全监察委员会: Data and Safety Monitoring Committee: |
无/No |